Survey
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
Chemical Messengers •Autocrine •self signal •Paracrine •neighbor signal •Endocrine •distant signal •Pheromone •airborne signal •same species •Allomone •airborne signal •different species Endocrine Glands Homeostasis Mechanism Receptors input signals skin responds to cold temperature sends signal to brain Control Center integrating center brain interprets temp signal makes you shiver Effectors output mechanism muscles shiver creating heat Neurotransmitters •Neuropeptides •Amines •Quaternary amines •Acetylcholine (ACh) •Monoamines •Catecholamines •Epinephrine (EPI) •Norepinephrine (NE) •Dopamine (DA) •Indoleamines •Serotonin (5-HT) •Melatonin •Amino acids •Gamma-aminobutyric acid (GABA) •Glutamate (GLU) •Glycine •Histamine (HIST) •Opioid peptides •Enkephalins (ENK) •Endorphins (END) •Peptide Hormones •Oxytocin (Oxy) •Substance P •Cholecystokinin (CCK) •Vasopressin (ADH) •Neuropeptide Y (NPY) •Brain-derived Neurotrophic factor •Hypothalamic Releasing Hormones •GnRH •TRH •CRH •Lipids •Anandamide •Gases •Nitric Oxide (NO) Acetylcholine Synthesis Breakdown Cholinergic Synapse • Choline • Acetyl CoA • Cholinesterase (ChAT) • Acetylcholinesterase (AChE) • Choline transporter • Vesicular ACh transporter (VAChT) Cholinergic (Ach) System Cholinergic Receptors • Nicotinic receptors • Muscle Type • • • • CNS Type Muscarinic receptors • M1 • • Iontotropic • • Blood vessels Lungs Exocrine Glands M4 • • Heart M3 • • • metabotropic CNS Autonomic ganglia M2 • • CNS M5 • Nicotinic ACh Receptor Neuromuscular junction Autonomic ganglia CNS Catecholamine Synthesis Noradrenergic (NE) System Noradrenergic Receptors • Alpha 1 receptors • • • • • • Alpha 2 receptors • • • Heart kidneys Beta 2 receptors • • • • • • • brain Beta 1 receptors • • All metabotropic Smooth muscle Skin GI tract Kidney brain Lungs GI tract Liver uterus Vascular smooth muscle Skeletal muscle Beta 3 receptors • Fat cells Dopaminergic Synapse • Tyrosine • Tyrosine Hydroxylase • DOPA • Aromatic Amino Acid Decarboxylase • Dopamine Transporter • Vesicular Monoamine Transporter • D2 Autoreceptor Dopaminergic (DA) System 1 Mesolimbic * Ventral Tegmental Area (VTA) Dopaminergic (DA) System 2 Mesostriatal * Basal Ganglia Dopaminergic Receptors • D1 receptors • D2 receptors • D3 receptors • D4 receptors • D5 receptors Serotonin (5-Hydroxytryptamine) (5-HT) Serotonergic Synapse • Tryptophan • Tryptophan hydroxylase • 5-HTP • Aromatic l-amino acid decarboxylase (AADC) • 5-HT • 5-HT transporter • 5-HT autoreceptor Serotoninergic (5-HT) System Serotonergic Receptors • • • • • CNS 5-HT7 receptors • • • 5-HT1B receptor CNS 5-HT6 receptors • • CNS PNS GI Tract 5-HT5A-B receptors • • CNS PNS GI Tract 5-HT4 receptors • • • • Metabotropic CNS PNS Blood Vessels GI Tract 5-HT3 receptors • • • • CNS Blood Vessels 5-HT2A-C receptors • • • • • • Iontotropic 5-HT1A-F receptors CNS Blood Vessels GI Tract Glutamate Synthesis • Glutamine • Glutaminase • Glutamic Acid • Glutamate • Aspartic Acid • Aspartate Glutamate Synapse Glutamate Receptors • AMPA receptors • • Kainate receptors • • GluK1-5 NMDA receptors • • • • GluA1-4 GluN1 GluN2A-C GluN3A-B Metabotropic receptors • mGluR1-8 Iontotropic Metabotropic AMPA Receptor Long-Term Potentiation (LTP) each triangle represents a single action potential Slope of the EPSP (one characteristic measure of an action potential) baseline response potentiated response Hippocampus has a three synaptic pathway Stimulate one area (mossy fibers) and record the action potentials in another (CA1) Stimulate multiple times to get a baseline response Once a stable baseline is established give a brief high frequency stimulating pulse Use the same stimulating pulse as in baseline but now see a potentiated response This potentiated response can last hours, days, or even weeks (LTP) Normal Synaptic Transmission Glutamate Channels: NMDA Mg2+ block no ion flow AMPA Na+ flows in depolarizes cell LTP Induction With repeated activation the depolarization drives the Mg2+ plug out of the NMDA channels Ca2+ then rushes in through the NMDA channels Ca2+ stimulates a retrograde messenger to maintain LTP Ca2+ also stimulates CREB to activate plasticity genes LTP-induced Neural Changes Neurobiological Changes via Learning Dendritic changes: •Increased dendritic arborization •Increased dendritic bulbs Synaptic changes: •More neurotransmitter release •More sensitive postsynaptic area •Larger presynaptic areas •Larger postsynaptic areas •Increased interneuron modulation •More synapses formed •Increased shifts in synaptic input Physiological changes: •Long-Term Potentiation •Long-Term Depression GABA Synthesis • Glutamate • Glutamic Acid Decarboxylase (GAD) • GABA GABA Synapse GABA Receptors • GABAA receptors • GABAB receptors • GABAC receptors Iontotropic Metabotropic GABAA Receptor GABAA receptor properties • Benzodiazepines (BDZ) and barbiturates cause sedation and reduced anxiety by binding to modulatory sites on the GABA receptor complex • BDZ binding sites are widely distributed in the brain. • They are in high concentration in the amygdala and frontal lobe. • Natural differences in anxiety levels are correlated with the number of BDZ binding sites. • PET scans of patients with panic disorder show less benzodiazepine binding in the CNS, particularly in the frontal lobe. GABA and Anxiety The Science of Drug Action Pharmacology: study of the actions of drugs and their effects on living organisms. Neuropharmacology: study of drug-induced changes in nervous system cell functioning. Psychopharmacology: emphasizes drug-induced changes in mood, thinking, and behavior. Neuropsychopharmacology: identifies chemical substances that act on the nervous system to alter behavior. . The Science of Drug Action Drug action: molecular changes produced by a drug when it binds to a target site or receptor. Drug effects: The molecular changes that alter physiological or psychological functions. Therapeutic effects: the drug–receptor interaction produces desired physical or behavioral changes. Side effects: all other non-therapeutic effects. Specific drug effects: are based on physical and biochemical interactions of a drug with a target site in living tissue. Nonspecific drug effects: are based on certain unique characteristics of the individual, (e.g., mood, expectations, perceptions, attitudes, placebo effects). Therapeutic Index Effective dose dose of a drug that produces a meaningful effect in some percentage of test subjects ED50 = effective dose for half the animals in a drug test Lethal dose dose of a drug that has a lethal effect in some percentage of test subjects LD50 = lethal dose for half the animals in a drug test Therapeutic index = LD50/ED50 Always greater than one Most drugs have an LD1 well above the ED95 Pharmacokinetic Factors 1. Drug Route of Administration 2. Absorption and Distribution • Lipid Solubility • Ionization • pH • Stomach Content • Gender • Other • • BBB Placenta 3. Drug Binding • Drugs bind to proteins in blood, or temporarily stored in bones or fat cells (inactivating drug) • Reduces the concentration of drug at site of action • Competition of binding can alter the concentration of free active drug potentially leading to overdose • Drug is not altered by liver enzymes • Can terminate action of drugs 4. Inactivation (Biotransformation) 5. Excretion • Organs: – – – – Intestines Kidneys Lungs Sweat glands • Products: – – – – – Feces Urine Water Vapor Sweat Saliva Mechanism of Drug Action Effects on specific neurotransmitter systems: Drugs may alter the availability of a neurotransmitter by changing the rate of: • • • • Synthesis Metabolism Release Reuptake Drugs may activate or prevent the activation of a receptor Drugs can acts as Agonists Normal receptor at rest, channel is closed Agonist binds and has same effect as endogenous neurotransmitter, channel opens Neurotransmitter binds receptor and opens channel Drugs can act as Antagonists Typical antagonist binds in place of endogenous neurotransmitter, prevents neurotransmitter action Non-competitive binding antagonist doesn’t interfere with neurotransmitter binding but still prevents neurotransmitter action Presynaptic Drug Actions 8. Blockade of NT degradation MAO inhibitors Prozac Chemical Weapons Postsynaptic Drug Actions